tyrosine kinase
Kingston P, Blauvelt A, Strober B, Armstrong AW. Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis. J Psoriasis Psoriatic Arthritis. 2023 Oct;8(4):156-165.[...]
Department of Medicine
A community resource for faculty and staff